Kintara Therapeutics Inc - KTRA Enterprise Value-to-Sales Ratio

Official company branding of kintara.com (KTRA)

Kintara Therapeutics (KTRA) is building a unique pipeline of treatments to combat rare brain tumors. The preparation of final molecular tests relies on the services of external CRO partners. The EV-to-revenue multiple demonstrates the enterprise value, where the current level is 0.00. Meanwhile, the business operates on a virtual model, fully delegating chemical filling and research to third-party CMO laboratories.

Kintara Pharma (KTRA): Company Value to Revenue from 11/23/2025 to 11/20/2026

Kintara - analytical breakdowns and key metrics (KTRA)

- cash balance and cash flow data:
Fundamental company valuation:KTRA, kintara.com
Manufactured products of Kintara Therapeutics Inc

To identify the fundamental drivers of stability for Kintara Therapeutics (KTRA), one should analyze the Enterprise Value to revenue ratio, which eliminates the impact of debt load and reflects the actual market price per unit of sales. The valuation trend of the enterprise via EV/Sales allows for an assessment of the capitalization potential of Kintara Therapeutics, considering the scalability of antitumor drug synthesis and the low cost of their mass production.